Erik Knudsen

Chairperson/Associate Director of Basic Science

Roswell Park Comprehensive Cancer Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (42)

Year:

2026

PURPOSE In both the early and advanced settings, cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are approved for use in hormone receptor–positive/human epidermal growth factor receptor 2–negative (HER2–) breast cancer (BC) in combination with endocrine therapy and increase the duration of invasive disease-free survival and progression-free survival (PFS). The duration of response to these treatments is variable between individual patients, supporting the use of biomarkers to inform treatment. Here, we investigated plasma thymidine kinase activity (TKa) as a continuous prognostic and predictive biomarker of response to CDK4/6 inhibitor–based therapy in early and advanced hormone receptor–positive/HER2– BC. MATERIALS AND METHODS TKa levels were assessed longitudinally at baseline, on treatment, and post-treatment on plasma samples from 80 metastatic and 28 high-risk patients receiving CDK4/6 inhibitor–based therapy as the standard of care. Patients were enrolled in the prospective observational Roswell Park Ciclib Study (ClinicalTrials.gov identifier: NCT04526587 ). RESULTS In the metastatic setting, TKa levels in baseline samples were inversely associated with the duration of PFS (hazard ratio, 1.91, P = .03). There was also a reduction in TKa levels from baseline to on-treatment in metastatic disease that displayed longer PFS (≥20 months; 120.7 DiviTum units of activity, DuA v 30.6 DuA, P = .028). Individuals with metastatic disease that displayed shorter PFS (≤8 months) presented with higher TKa values on treatment (220.2 DuA v 30.6 DuA, P = .008) compared with patients with longer PFS. In early-stage high-risk cases, TKa values were lower on treatment compared with baseline (41.4 DuA v 114.8 DuA, P = 3.55e-08). CONCLUSION These findings support further investigation of circulating TKa levels as a continuous prognostic and predictive biomarker of response to CDK4/6 inhibitor–based therapy. Future studies are well-suited to assess definitive TKa cutoff values to inform treatment decisions.

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

PURPOSE The PENELOPE-B trial (ClinicalTrials.gov identifier: NCT01864746 ) recruited patients with hormone receptor+/human epidermal growth factor receptor 2– early breast cancer without a pathological complete response after taxane-containing neoadjuvant chemotherapy and at a high risk of relapse. Patients were randomly assigned (1:1) to receive 13 cycles of palbociclib once daily or placebo on days 1-21 in a 28-day cycle in addition to endocrine therapy (ET). PENELOPE-B did not show improved invasive disease-free survival (iDFS) after adding palbociclib to ET. This retrospective analysis investigated the impact of germline pathogenic variant (PV) status of BRCA1/2 and non- BRCA1/2 cancer predisposition genes on the outcomes of PENELOPE-B trial patients. METHODS In total, 445 patients were sampled following a case-cohort design and 442 were analyzed for germline PVs. Statistical analyses were performed for time-to-event end points (iDFS, distant disease-free survival [DDFS], and overall survival [OS]). RESULTS Of the 442 patients, 42 carried PVs in any cancer predisposition gene; 15 carried BRCA1/2 PVs. Irrespective of the treatment arms, PV status was not a prognostic factor. Regarding the treatment arms in BRCA1/2 PV carriers, numerically better 3-year outcomes were observed in the palbociclib arm (iDFS, 95%; DDFS, 95%; OS, 100%) than in the placebo arm (iDFS, 72.8%; DDFS, 72.8%; OS, 87.5%; hazard ratios palbociclib v placebo 0.349 [iDFS] and 0.562 [DDFS], not calculated for OS, too few events). In patients without BRCA1/2 PVs, the differences in 3-year outcomes were negligible. PVs in non- BRCA1/2 cancer predisposition genes did not influence the efficacy of palbociclib, although gene-specific effects could not be excluded. CONCLUSION Patients with BRCA1/2 PVs had numerically better outcomes after palbociclib. However, the number of BRCA1/2 carriers was small. Larger randomized clinical trials should consider the PV status to further evaluate whether BRCA1/2 PV carriers benefit from cyclin-dependent kinase 4 and 6 inhibitor treatment.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (24)

Agnieszka Witkiewicz

Professor of Pathology and Oncology

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Sheila Stewart

Professor

Washington University in St. Louis

UNITED STATES
View details

Pankaj Singh

Professor and Chair

University of Oklahoma Health Sciences Center

UNITED STATES
View details

Michael Feigin

Assistant Professor

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Scott Powers

Professor

Stony Brook University

UNITED STATES
View details

Alice Soragni

University of California

UNITED STATES
View details

Mark Long

Assistant Professor of Oncology

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Katerina Gurova

Associate Professor

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

David G. DeNardo

Professor of Medicine

Washington University School of Medicine

UNITED STATES
View details

Karen McLean

Professor

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Seock-Ah Im

Professor

Seoul National University College of Medicine

SOUTH KOREA
View details

Seth M. Rubin

University of California

UNITED STATES
View details

Jeffrey Tyner

Professor

Oregon Health & Science University

UNITED STATES
View details

Prasenjit Dey

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Ethan Abel

Associate Member/Associate Professor

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Karen A. Gelmon

The University of British Columbia

CANADA
View details

Sheheryar Kabraji

Associate Professor

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Deborah Novack

Professor

Washington University in St. Louis

UNITED STATES
View details

Corinna Ernst

Hannover Medical School

GERMANY
View details

Gregory Longmore

Professor

Washington University in St. Louis

UNITED STATES
View details

Ioannis Sanidas

Principal Investigator

Massachusetts General Hospital

UNITED STATES
View details

Miguel Martin

Universidad Complutense de Madrid

SPAIN
View details

Xingxing Zang

Albert Einstein College of Medicine

UNITED STATES
View details

Donghwa Kim

University of California, San Francisco

UNITED STATES
View details